Latest Breaking News On - Rare disease clinical research network - Page 1 : vimarsana.com

Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data The research demonstrated that treatment with FT011 results in a remarkable reversal in the activation of genetic markers associated with fibrosis Fibrosis is responsible for 45 percent of all deaths globally - FT011 is a novel drug with potential to treat chronic fibrosis in multiple organs such as the kidneys, skin, lungs, heart, and eyes Certa Therapeutics is a clinical stage biotechnology company based in Melbourne, Australia, developing innovative therapies for the treatment of fibrotic diseases ANN ARBOR, Mich., Nov. 4, 2022 /PRNewswire/ New research presented today by the University of Michigan reveals ground-breaking results for Certa Therapeutics' FT011, a novel potential treatment of serious inflammatory and fibrotic diseases. The results in a chronic kid

United statesMatthias kretzlerDarren kellyRare disease clinical research networkNational centerNephrotic syndrome study networkTranslational sciencesUniversity of michiganNephcure kidney internationalUniversity of michigan medical school professorHalpin foundationAmerican society of nephrologyUniversity of michigan medical schoolAlport syndrome foundationMichigan medical schoolCerta therapeutic